accessDx
redefining personalized therapy

Respiratory Pathogen Panel

Detects and differentiates respiratory pathogens
A single multi-pathogen assay with results in 3-7 days

The Respiratory Pathogen Panel

Acute respiratory infections represent a significant cause of morbidity and mortality in young, geriatric, immunocompromised patients, or those with chronic pulmonary diseases. Viral and bacterial infections have overlapping clinical presentations making a definitive diagnosis difficult. Moreover, co-infections are also common and access to advanced technology is essential to precisely detect multiple pathogens at once. False negative test results can lead to a delayed diagnosis and poor clinical outcomes. Furthermore, rapid and precise pathogen identification is essential to effectively control the spread of an infection in a community.

Traditional diagnostic techniques such as virus cultures or enzyme immunoassays, once the mainstays for pathogen detection, are either insensitive, time consuming, labor intensive or operator dependent. Multiplex PCR has emerged as a validated strategy for the rapid detection and precise identification of a large number of respiratory pathogens.

High Diagnostic Accuracy

The Respiratory Pathogen Panel quickly detects and differentiates viral and bacterial pathogens so effective treatment can begin sooner The Respiratory Pathogen Panel utilizes quantitative Real-Time PCR to analyze your patient's nasal sample and reports results in 3-7 days. The test precisely identifies 24 respiratory viruses and 10 bacterial species from a single specimen which allows providers to accurately diagnose patients and precisely prescribe timely and effective treatments. Take advantage of advanced diagnostic capabilities and add an option for COVID-19 testing to ensure a single test is needed to diagnose and manage your patient.

Improves clinical confidence and decreases patient risks

- Provides a more definitive diagnosis than POC antigen assays
- Detects polymicrobial infections
- More accurate than conventional culture[1]
- Unaffected by concurrent antibiotic use
- Aids in quick clinical decision-making
- Improves infection isolation and surveillance strategies
- Supports epidemiologic monitoring
- Reduces false negative results
- Reduces unnecessary antibiotic use
- Allows targeted early-use of antivirals
- Helps avoid unnecessary hospitalizations

The AccessDx RPP Difference

Our RPP test guarantees a 3-7 days turn-around result once received, so you can rapidly establish treatment plans and isolation strategies with results from a single test. AccessDx is CAP and CLIA certified, showcasing our commitment to accuracy, speed, and excellence. With over 1,000 clients across the healthcare landscape, our partners recognize our commitment to excellence. AccessDx's dedicated lab operations and client success teams are ready to help serve the needs of your group.

RPP Test Panel

Viruses Detected

Adenovirus
Human Bocavirus
Human Coronavirus 229E
Human Coronavirus HKU1
Human Coronavirus NL63
Human Coronavirus OC43
Human Enterovirus
Human Enterovirus D68
Human Herpesvirus 3
Human Herpesvirus 4
Human Herpesvirus 5
Human Herpesvirus 6
Human Metapneumovirus
Human Parainfluenza virus 1
Human Parainfluenza virus 2
Human Parainfluenza virus 3
Human Parainfluenza virus 4
Human Respiratory Syncytial Virus A
Human Respiratory Syncytial Virus B
Human Rhinovirus
Influenza A
Influenza A/H1-2009
Influenza A/H3
Influenza B

Bacteria Detected

Bordetella bronchiseptica / parapertussis /pertussisp
Bordetella pertussis
Chlamydophila pneumoniae
Haemophilus influenzae
Klebsiella pneumoniae
Legionella pneumophila
Mycoplasma pneumoniae
Staphylococcus aureus
Streptococcus pneumoniae

[1]Henrickson, K. J. (2004). Advances in the lab diagnostics of viral respiratory disease. Ped Inf Dis J 23: s6-s10. s6-s10. 065-09JAN2018